The objective of this study was to assess efficacy and safety of percutaneous ultrasound (US) guided preferential radiofrequency ablation (PRFA) in early breast carcinoma under local anesthesia and to evaluate a new assessment protocol. Eighteen breast cancer patients were enrolled in order to receive PRFA treatment three weeks prior to resection. Pain assessment was performed using the visual analoge scale. Analysis of treatment success was performed using magnetic resonance imaging (MRI) as well as histological assays for hematoxylin & eosin (H&E) and cytokeratine 8 (CK8). In a subset of patients contrast enhanced ultrasound (CEUS) was performed before and after treatment. MRI showed no residual tumor growth in 100% (18/18) of cases. Complete tumor devitalization was indicated in 83% (15/ 18) of patients as judged by H&E staining and in 89% (16/18) as judged by immunostaining for CK8. In 100% (18/18) at least one histologic method showed devitalization in the entire tumor. Treatment was well tolerated. Pain experienced during the procedure was mild. US-guided PRFA of small breast carcinoma is feasible under local anesthesia. MRI and CK8 have proven valuable additions to the RF breast tumor ablation protocol. CEUS shows potential as a modality for radiological follow-up.
Introduction
Globally an estimated 1.64 million women were diagnosed with breast cancer in 2010 with incidence increasing most markedly in developing countries resulting from a change in lifestyle conditions, reproductive patterns, increasing average age and use of hormone replacement. While mortality is comparatively high in developing countries it remains constant or is falling in developed countries due to advances in medication and radiotherapy as well as tumor detection in earlier stages as a result of screening programs. In Sweden, which was one of the first countries to implement a national screening program in 1986, the median tumor size in breast cancer patients diagnosed 2011 was 17 mm. There is a general trend towards less invasive treatment regimes. Lumpectomy followed by radiation therapy is the preferred surgical treatment in women with unifocal breast cancer if the procedure is expected to yield a cosmetically acceptable result. Sentinel lymph node biopsy has replaced axillary node clearance as the gold standard for staging of the axilla. In the wake of this development, minimally-invasive technologies for breast cancer treatment have been studied using several different approaches. Radiofrequency ablation (RFA) seems to be the most promising technology given its constantly high success rates, short treatment time, low complication rates [1] and preferential destruction of tumor tissue as compared to surrounding fatty tissue [2] .
However, several issues remain to be addressed before the modality can expect widespread acceptance. Histological assessment of RF treatment success is problematic. Standard H&E staining proves unreliable when assessing RF treatment success [3] , generally underestimating RF damage when performed shortly after treatment [4, 5] . Mammography and US are unsuitable to radiologically evaluate treatment outcome [6, 7] . Futhermore, while there is ample data on treatment under general anesthesia, experience is limited concerning treatment under local anesthesia in an outpatient setting. Finally, although precision placement of the electrode is crucial [8] there are currently no means available to facilitate the cumbersome process of manual large diameter electrode placement. Based on initial institutional experience in the use of PRFA in breast cancer patients [2, 9] the goal of this study was to move the treatment into an outpatient setting and tackle the identified shortcomings. The radiological protocol for patient selection and treatment follow-up was improved by including MRI and CEUS. Histological assessment was performed using CK8 immunohistochemistry as well as H&E and means for powerassisted precision placement were introduced to aid the placement of the treatment electrode.
Materials and methods

Patients
Patients included in our study had to be diagnosed with a unifocal, clearly distinguishable tumor with a maximum diameter of 16 mm as assessed by mammography, US and MRI. Exclusion criteria included multifocality, diffuse growth patterns, tumors with surrounding ductal carcinoma in situ (DCIS) and lobular cancer. In line with ongoing clinical trials on minimally-invasive ablation technologies at the time (e.g. trial NCT00723294) the inclusion criteria were altered during the course of the study to enable the inclusion of patients with tumors that were ER/PR negative, Her2/ neu positive, of Elston grade 3, had a size of 2 cm and showed 25% of intraductal components. The study was approved by the Regional Ethics Committee of Stockholm, Sweden (Ref. nr. 2008/ 1018-31/3; 2010/963-32) and all procedures were performed in accordance with the ethical standards of the World Medical Association (Declaration of Helsinki). If the patient fulfilled the inclusion criteria, detailed written information about the study was given. If the patient agreed, a written consent was obtained. Core biopsy samples prior to PRFA treatment were retrieved and analyzed regarding histological type, Elston grade and receptor status (estrogen receptor, progesterone receptor, Her2/neu, Ki67 and CK8).
RF treatment instrumentation
Radio frequency heating can be utilized to act preferentially in breast cancer tumors, heating tumor strands relatively more than surrounding non-tumor tissue [2] . It is therefore named preferential radiofrequency ablation (PRFA). Successively developed prototypes (NeoDynamics AB, Sweden) incorporating an internally cooled electrode design were used. The instrumentation is approved by the Medical Products Agency, Uppsala, Sweden (Ref. code 561:2010/503820) for the purpose of this study and conforms to the international safety norm EN 60601-1. In a previous study at our institution it was reported that the insertion procedure of the needle was problematic in certain cases due to a hard consistency of the tumor in comparison to the surrounding soft fatty tissue [9] . Since correct placement of the treatment electrode is crucial for optimal treatment, a handheld driver unit for power-assisted insertion of the electrode as well as a specially designed treatment electrode was developed. The driver unit aids the operator by delivering triggered mechanical pulses thrusting the needle forward over a controlled millimeter distance when encountering hard to penetrate tissue.
Imaging modalities
For MR imaging a 1.5 T (Signa HDxt, GE Healthcare, USA) system was used in combination with an intravenous gadolinium contrast agent (ProHance, Bracco Diagnostics, Italy). Ultrasonographic (US) imaging was performed with an iU22 ultrasound device (Philips, Netherlands) together with transducer L17-5 (17-5 MHz frequency range) for common US and L9-3 (9e3 MHz frequency range) for contrast-enhanced ultrasound (CEUS). The latter involved an intravenous administration of sulfur hexafluoride microbubbles with a size of 1e10 mm (Sonovue, Bracco Diagnostics, Italy).
Treatment protocol
The first four cases were treated in the operating theatre at the department of surgery. Treatment was performed under local anesthesia with means for administration of additional sedation/ analgesia available. In the inpatient setting patients routinely received 1 g paracetamol and 25 mg meclozine before thermal ablation. Upon discharge patients received 5 mg oxycodone and 500 mg paracetamol according to routine department protocol. Subsequent 14 patients were treated in an outpatient setting at the department of mammography. 40e75 ml of mepivacaine (5 mg/ml) and bupivacaine (2.5 mg/ml) combined with 5 mg/ml epinephrine were injected at the insertion site as well as adjacent to the tumor for pain control and to alienate the tumor from the skin and pectoral muscle. Tissue temperature was kept at 85 C for 10 min. Electrical impedance was monitored in order to improve thermal lesion control. To avoid thermal damage skin temperature was monitored using a handheld 650 nm laser guided IR thermometer. Ice was used for cooling. As suggested by several authors [8, 9] , the electrode was routinely active upon retraction in order to prevent possible seeding of disseminated tumor cells.
Pain assessment protocol
In order to quantify perceived pain resulting from PRFA treatment under local anesthesia a measurement was performed using the visual analoge scale (VAS, from 0 to 10; 0 ¼ no pain, 10 ¼ unbearable pain). Since the VAS is less useful for comparative analysis across a group of individuals at one time point, but more suitable for comparing events in a single individual, pain assessment was performed at four different stages during the procedure. The patient was specifically asked to judge pain before treatment, during administering of local anesthetics, during PRFA treatment and after completion of the procedure. Furthermore, if there was any discomfort whatsoever between the time of PRFA treatment and surgery, it was noted.
Radiological and histological assessment
MRI was performed before and after PRFA treatment close to the date of surgery. In a subset of six patients CEUS was performed before and after PRFA treatment. PRFA treatment was carried out by an experienced radiologist. Resected specimens underwent radiography to evaluate extent and surgical margins. Subsequently specimens were fixed in 4% buffered formalin and cut into 3e4 mm slices. Sheaves containing the necrotic lesion were identified, trimmed, paraffin embedded and processed into 4 mm sections. For histopathological evaluation using H&E the sections were stained following validated standard hospital protocol. For immunohistochemical staining paraffin embedded sections were stained with a monoclonal antibody to CK8 (35betaH11, Ventana Medical Systems, Inc., Tucson, USA) using validated hospital standard protocol. A trisbased buffer with a slightly basic pH (Cell Conditioning 1, Ventana Medical Systems, Inc.) was used for pre-treatment. Sections were subsequently counterstained with Hematoxylin II as well as Bluing Reagent (Ventana Medical Systems, Inc.) and finally fixated and mounted. An automated Benchmark XT (Ventana Medical Systems, Inc.) staining instrument was used for the immunohistological staining procedure. Radiologic and histopathologic assessment was performed by an experienced specialist. In case of uncertainty, a second experienced physician was consulted and agreement achieved.
Statistical analysis
Given the low sample size, statistical evaluation of pain measurements was aided by substituting missing values with median values from each measurement stage. A Wilcoxon Signed-Rank test (alpha ¼ 0.05) was performed for comparing perceived pain during administration of local anesthetics with pain during PRFA treatment as well as pain before and after treatment.
Results
For characteristics of patients enrolled in this study see Table 1 . All patients except for one were scheduled for subsequent breastconserving surgery and sentinel lymph node biopsy (SLNB), radiotherapy and systemic endocrine treatment. One patient was planned to be treated with mastectomy without subsequent radiotherapy since the tumor was located in the centre of a small breast.
After PRFA treatment, MRI showed no residual tumor growth in 100% (18/18) of cases. Complete devitalization of the tumor was indicated in 83% (15/18) of patients as assessed by H&E staining and in 89% (16/18) as assessed by immunostaining for CK8. Treatment was performed in a median of 10 min (range 8e14) with postoperative swelling wearing off after approximately 30 min. No adverse events were reported. In the inpatient setting patients could leave the hospital on the same day. In the outpatient setting patients were able to leave after approximately one hour. Perceived pain related to the procedure varied strongly. Taken together, pain experienced during PRFA treatment can be considered mild with a median value on the VAS of 2.5. Pain did not differ significantly when comparing injection of local anesthetic and thermal ablation of the tumor with median values of 2 and 2.5 respectively (n ¼ 18, Z ¼ À0.656, p ¼ 0.512). The median value of pain reported by the patient before and immediately after treatment was 0 and 0.5 respectively with the difference being significant in this case (n ¼ 18, Z ¼ À2,032, p ¼ 0.042). Table 2 gives a detailed account of pain management and assessment.
Judged by H&E staining most cases showed frank necrosis or regressive changes compatible with devitalization of the entire tumor and surrounding mesenchyme. In three patients this was not the case. In patient nr. 3 the tumor was partially affected with necrosis in surrounding fatty tissue including adjacent intraductal cancer, but areas of the tumor had a viable appearance with no signs of necrosis. Patient nr. 7 showed no signs of devitalization and in patient nr. 18 the tumor was interpreted viable although certain effects of treatment could be traced. However, when using CK8 staining no immunoreactivity was present. Fig. 1 illustrates CK8 immunostaining of a biopsy sample before and of the entire tumor after treatment showing considerable distinction between viable and non-viable epithelium. Using CK8 immunostaining the tumor was interpreted as viable after treatment in two cases. In patient nr. 12 sparse staining was observed in areas throughout the tumor illustrating a nonspecific CK8 staining in an otherwise clear-cut regressive tumor (Fig. 2) . In patient nr. 5 a slightly more distinct staining was present in around 75% of the tumor (Fig. 3) . In one patient CK8 status before PRFA was not analyzed since not enough tissue was present in the biopsy sample.
MRI was performed with a median of 13 days (range 6e21) after PRFA treatment, shortly before resection, which was carried out with a median of 14.5 days after PRFA treatment (range 6e22). In all cases the contrast enhancement in the target area had disappeared indicating complete treatment response. An ablation cavity could be seen surrounded by a peripheral ring as reported by other authors [10] . In two patients the MRI procedure before PRFA treatment lead to additional diagnostic investigations. In one of these an MRI-guided biopsy was performed to assess a suspicious lesion and in the other patient a contralateral diagnostic partial mastectomy was performed due to suspicion of intracystic malignancy. In both cases findings were benign. CEUS images before treatment were heterogeneous, reflecting different vascularization patterns and tissue properties of the tumor and surrounding tissue. After treatment, CEUS images showed a clearly distinguishable ablation margin (see Fig. 4 ). In all six cases when CEUS was used the radiologist judged the ablation to be successful.
Discussion
Today, RFA is routinely used in cancer management. In the liver it is a valuable curative treatment option for patients with unresectable hepatocellular carcinoma and has gradually started to be used to treat resectable tumors [11] . It has been included as an 
option into the treatment guidelines for small renal carcinoma in patients with high surgical risk [12] and is available for high-risk operable and medically inoperable lung cancer patients [13] . Furthermore, it is widely used in a both curative and palliative setting for metastatic disease. Since the first reported RFA treatment in the breast in 1999 [14] numerous studies with different treatment protocols, follow-up routines, imaging modalities, inclusion criteria and settings have been performed. RFA performed under local anesthesia was first reported by Burak [15] with several studies following [6,16e23] . Most of the studies used sedation in addition to local anesthesia including the only one that reported quantified data on perceived pain during the procedure [17] . Our data suggest that treatment under local anesthesia is feasible with only mild pain perceived by the patient. For radiological assessment MRI was the most significant improvement introduced in RF treatment of the breast since its inception. MRI has been proposed as a tool both for patient selection, especially to exclude patients with extensive intraductal carcinoma (EIC) [9] , as well as a modality to evaluate therapeutic effect [10, 20] where it was reported to reliably predict histologic findings [24] . None of the patients in our study showed EIC. However, in two patients MR imaging prior to PRFA treatment lead to additional suspicious findings and related costly diagnostic interventions. Both findings were false-positive. While MRI delivers decent results in patient selection, the additional costs and patient discomfort of this modality should not be underestimated. Contrast-enhanced ultrasound could be an alternative. It is today a recognized tool for evaluating the immediate treatment effect and guidance for subsequent immediate re-treatment in the RF ablation of lesions in the liver [25] . Our preliminary results concerning the use of CEUS are promising with post-treatment images suitable for depicting ablation margins.
Histopathologic judgment of treatment success remains a challenge. A general problem of the widely used H&E staining is the lack of an established protocol for evaluating thermally ablated specimen [26] and the underestimation of cell devitalization level when used less than six month after ablation [5] . Enzyme histochemical analysis of cell viability using nicotinamide adenine dinucleotide (NADH)-diaphorase analysis was successfully performed in several studies [1] but requires frozen tissue which is scarcely available due to the advanced infrastructure necessary. It has poor morphology compared to paraffin sections and does not work well for fatty tissues like breast, since fat hampers the cutting of frozen sections [5, 27] . It has recently been shown that the ability to assess cell viability using immunostaining for CK8 in paraffin embedded section is comparable to NADH-diaphorase staining in frozen ones [27] . Two studies have previously used CK8 immunohistochemistry to determine cell viability after RFA in the breast with good results [8, 15] . CK8 immunostaining showed promising results in our study and could be an alternative to the more costly and cumbersome NADH-diaphorase staining assay. Since a small percentage of breast tumors are stated to be CK8 negative [28] core needle biopsy samples must be analyzed for CK8 positivity before ablation.
In our opinion, three independent methods should establish reasonable certainty concerning tumor tissue denaturation. Radiologic imaging using MRI or CEUS is used for depicting the physical boundaries of the ablated region. Images and/or video clips before ablation should be stored to enable exact comparison. Histologic methods using H&E staining are used for judging morphology and finally CK8 immunostaining for assessing cell viability. Given their respective advantages, we suggest to focus further research on CK8 immunochemistry and CEUS for histological and radiologic follow-up respectively, since they leverage the advantages of a minimally-invasive modality with respect to increased patient comfort and cost-efficiency. A high level of accuracy is required to insert and properly position the treatment electrode inside the tumor [8] . Inprecise positioning can lead to failed treatment procedures [9, 24] . To date, the power-assistance device was introduced into the protocol for the last two patients Fig. 2 . In patient nr. 12 the biopsy shows clear positivity for CK8 (A, magnification 4Â) prior to treatment. After treatment, a light brown staining can be seen throughout most of the tumor (B, magnification 10Â). However, when looking at the H&E staining (C, magnification 10Â) it can be assessed that the tumor is completely devitalized with significant changes with hyaline degeneration and loss of nuclear chromatin pattern in the connective tissue and tumour epithelium illustrating an example of unspecific immunostaining of CK8. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 3 . In patient nr. 5 a marked CK8 staining can be observed in the biopsy taken before PRFA treatment (A, magnification 4Â). After treatment, staining persists in certain areas of the tumor as can be seen in the image showing the complete tumor (B, magnification 0.3Â) as well as in a close-up (C, magnification 10Â). However, staining is less distinct than in the biopsy before treatment and signs of coagulation can be observed in the area. When comparing the slides using H&E staining before (D, magnification 40Â) and after treatment (E, magnification 40Â) it can clearly be stated that morphological properties in both epithelial and connective tissue indicate denaturation. As previously discussed, adipose tissue seems to be disproportionally unaffected as can be noted by morphologically viable fat cells surrounded by denaturated cancer cells (F, magnification 20Â). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) and no conclusion can be drawn considering improved treatment results. However, evidence from these two cases points towards an improved operator control over the introduction process and optimal positioning of the electrode. Further studies using this technology will yield decisive data.
As development progresses and evidence of efficacy increases, e.g. through randomized control trials, radiofrequency ablation has the potential to become a tool for the treatment of small breast carcinoma. As has been the case in liver and kidney lesions, prior to minimally-invasive ablation treatments having matured, patients with high surgical risk or those refusing surgical treatment could initially benefit from this treatment modality. Around 14% of breast cancer patients in Sweden are over the age of 80. This patient group poses specific challenges concerning surgery and hospitalization. They more often belong to risk groups concerning general anesthesia, are more cost-intensive due to co-morbidity, at a greater risk of acquiring infections, stay hospitalized longer and run the risk of mental confusion and depression due to loss of their home environment. A pilot study in this patient population is currently ongoing at our institution.
Conclusion
PRFA has the potential to be a safe and effective modality to treat early breast carcinoma. It can be performed under local anesthesia with minimal discomfort for the patient followed by discharge within 60 min. MRI, CEUS and CK8 immunostaining prove suitable additions to the protocol for patient selection and treatment assessment. An adequately powered randomized control trial comparing PRFA to routine breast conserving surgery with an appropriate follow-up period is necessary to provide sound evidence on local recurrence rate and side effects. PRFA could be a valuable modality for the treatment of patients with contraindications to surgery or those refusing a surgical resection of the tumor.
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